Longeveron LGVN 深 沪
已收盘 02-06 16:00:00 美东时间
0.513
+0.002
+0.39%
华盛通- 最 高0.531
- 今 开0.52
- 成交量 8.12万股
- 最 低 0.5101
- 昨 收 0.511
- 总市值 1094.38万
- 52周最高 1.9198
- 市盈率 静 --
- 换手率 0.38%
- 52周最低 0.492
- 委 比 -78.80%
- 总股本 2133.29万
- 历史最高 450.00
- 量 比 0.41
- 振 幅 4.09%
- 历史最低 0.492
- 每 手 1
- 风险率 0.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Grants Longeveron Type C Meeting At March End To Prepare For Anticipated Q3 Data Readout Of ELPIS II, Pivotal Phase 2 Clinical Trial Evaluating Laromestrocel For HLHS Treatment
ELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS II results are
01-26 22:17
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron Inc. announced that the U.S. FDA has granted a Type C meeting in March to prepare for the third-quarter 2026 readout of the ELPIS II pivotal Phase 2 clinical trial for its stem cell therapy, laromestrocel, targeting Hypoplastic Left Heart Syndrome (HLHS). The meeting aims to align on clinical efficacy data and statistical analysis to support a Biologics Licensing Application (BLA). Laromestrocel has received FDA designations including ...
01-26 14:15
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
Longeveron Inc., a clinical-stage biotechnology company, will participate in the StartUp Health Apollo House during JPM Healthcare Week 2026 as part of the Alzheimer’s & Brain Health Moonshot initiative. The event aims to accelerate breakthroughs in Alzheimer’s and Parkinson’s diseases, supported by organizations like ADDF and Gates Ventures. Longeveron will host meetings with investors and partners during the week.
2025-12-29 14:15
Longeveron Secures USPTO Patent For MSC Therapy Targeting Female Sexual Dysfunction
The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to female patients with sexual dysfunction in order to increase sexual quality of
2025-12-17 22:17
Longeveron Reports Phase 2 Data Showing Stem Cell Therapy Laromestrocel Reduces Neuroinflammation And Preserves Brain Structure In Mild Alzheimer's Disease, To Presented At The 18th Clinical Trials On Alzheimer's Disease Conference, Held December 1-4, 2025
Results obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel was associated with a reduction in MRI measured neuroinflammation compared to
2025-12-02 01:02
Longeveron To Present Alzheimer's Disease Data At Clinical Trials On AD Conference In California
Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its submission entitled
2025-11-19 22:17
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy
Longeveron Inc.获得美国专利第12,465,620号，涉及使用间充质干细胞治疗伴有炎症的年龄相关虚弱症。该专利有效期至2038年，可延长。年龄相关虚弱症表现为虚弱、低体力、运动迟缓、疲劳及体重减轻，与炎症相关。Longeveron的干细胞疗法Laromestrocel已完成临床试验，显示积极效果。
2025-11-12 14:05
Longeveron Inc. Earnings Call: Mixed Sentiments Amid Clinical Progress
Longeveron Inc. (($LGVN)) has held its Q3 earnings call. Read on for the main h...
2025-11-06 09:21
Earnings Preview For Longeveron
Longeveron (NASDAQ:LGVN) is preparing to release its quarterly earnings on Tues...
2025-11-04 05:03
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
Longeveron announced the full enrollment of its pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential treatment for hypoplastic left heart syndrome (HLHS), a rare and severe congenital heart defect. ELPIS II is expected to release top-line results in the third quarter of 2026, following encouraging outcomes from the Phase 1 trial, which showed 100% transplant-free survival in treated patients up to age five. The thera...
2025-10-27 13:15
